PubMed Health⌕ Search

Biomedical subjects

I Khalkhali

Publications and source records attributed to I Khalkhali.

16 recordsLinked to original sources
PubMed1997

Radionuclide-guided stereotactic prebiopsy localization of nonpalpable breast lesions with normal mammograms.

UNLABELLED: Scintimammography with 99mTc-sestamibi can be used as a complementary technique to improve the mammogram's sensitivity and specificity for detection of breast carcinoma. We have observed in some patients focal areas of increased 99mTc-sestamibi uptake with no corresponding abnormalities on physical examination or mammogram. A phantom device and a special needle were designed to stereotactically localize these lesions before biopsy. METHODS: After intravenous injection of 30 mCI (1110 MBq) of 99m Tc-sestamibi, a prone lateral image of the abnormal breast was obtained. With the patient in the prone position, the breast was compressed with two fenestrated plates in the prone position. The x and y coordinates of the abnormal hot spot of the breast were determined. The z coordinate of focal 99mTc-sestamibi uptake was determined by advancing a localizer needle through a selected predetermined hole of the fenestrated plate using real-time visualization on the persistence monitor. The tip of the opturator inside the needle is welded with 57Co to determine the depth of the hot spot in the breast. RESULTS: Three women, all of whom had normal mammogram and breast physical examinations, were studied using 99mTc-sestamibi prone breast imaging. Pre-excisional biopsy needle localization of abnormal focal uptake was performed. Two women demonstrated infiltrative ductal carcinoma, and the third had proliferative fibrocystic disease of the breast. CONCLUSION: Our initial experience demonstrates that nuclear medicine guided stereotactic needle biopsy of the breast in patients with positive scintimammograms is technically feasible. In the future, this technology will enable us to detect breast carcinoma in the absence of clear-cut clinical and mammographic findings.

Adult↗
PubMed1997

Scintimammography with Tc-99m sestamibi.

Mammography and physical breast examination are currently the most frequently and recognized screening tools for detection of breast carcinoma. These methods have been proved successful for early detection of breast cancer. Considering the 85% sensitivity associated with combined mammography and physical examination and a low positive predictive value of 20%-30% for diagnosis of breast carcinoma, there is a critical need for a more accurate, noninvasive imaging test to improve the sensitivity and specificity of mammography (7, 19, 20). Since early 1992, we have studied over 1200 women with clinically and/or mammographic abnormalities prior to breast biopsy and/or fine needle aspiration cytology of the breast. We have evaluated the role of Tc 99m Sestamibi as a complimentary procedure to conventional mammography in detection of breast carcinoma. The preliminary results of our studies have been published elsewhere (14, 17, 18). DuPont Merck Pharmaceutical Company in the USA on that basis, determined to conduct a multicenter clinical trial for the role of this radiopharmaceutical for the diagnosis of breast carcinoma in women with mammographically and/or clinically palpable abnormalities. This study was conducted at 42 institutions throughout the United States and Canada enrolling 673 women who where otherwise scheduled for breast biopsy and/or mastectomy. The preliminary results of this trial in both palpable and nonpalpable breast abnormalities are encouraging (24). Our most recent study on 157 women (mean age 47.9 years +/- 10.2) with 164 lesions with indications for histologic and cytologic analysis who underwent scintimammography with Tc 99m Sestamibi demonstrated the sensitivity of 92.3% and the specificity 87.5% (15). We have concluded that Scintimammography with Tc 99m Sestamibi can be used in conjunction with mammography to improve its specificity.

Adolescent↗
PubMed1997

Scintimammography: the new role of technetium-99m Sestamibi imaging for the diagnosis of breast carcinoma.

Technetium-99-Sestamibi scintimammography has emerged as a new procedure for the imaging of breast tumors. Currently, a large clinical experience has been developed and the results published. At the present time, the major drawback of this procedure appears to be its low sensitivity for the detection of breast carcinomas smaller than 1 cm in diameter. There are other biologic and technical issues that remain to be overcome to optimally image the breasts. Some of these include: development of a dedicated breast imager using nuclear medicine techniques, development of stereotactic needle localization of the abnormalities that demonstrate focal increase uptake in women with normal mammogram and breast physical examination, manufacturing of a breast compression device so that we can immobilize the breast in place for more adequate imaging, overcoming the issue of unilateral or bilateral diffuse breast uptake that is noted in 7-10 percent of the cases and finally, determination of optimal dose and imaging factors. This review includes our experience at Harbor-University of California, Los Angeles Medical Center with the use of this agent for breast imaging since 1992.

Breast↗
PubMed1996

Design and assessment of a scintigraphy-guided biplane localization technique for breast tumours: a phantom study.

The aim of this study was to design and assess a scintigraphy-guided stereotaxic localization technique for breast phantoms. We wished to develop and validate scintigraphically aided biopsy of non-palpable breast masses identified only by sestamibi scintimammography. A biopsy table was built for patients to lie prone with the breast in a dependent position. The breast can be compressed in the cranial and caudal directions by fenestrated paddles. Three freely adjustable radioactive reference lines, placed along the x, y and z axes, each containing about 30 MBq (800 micro Ci) 99Tcm, were mounted on sliding rules on the external frame which surrounded the phantom. The breast phantom was a semi-square-shaped sponge. Background activity was provided by a sponge cloth containing 37 MBq (1 mCi) 99Tcm solution. Non-palpable lesions were carved out of the same sponge and wrapped in thin plastic film, and labelled with about 11 MBq (300 microCi) 201T1. The lesions, 3-15 mm in size, were placed at random at phantom depths of 2-6 cm by an individual different from the person performing the localization. Scintigraphy-guided three-dimensional localization of the lesion was performed by acquiring two orthogonal images and superimposing the reference bars over the lesion image and thus identifying the exact x, y and z coordinates of the lesion. Using these coordinates, a 22 gauge needle, containing about 37 MBq (1 mCi) 99Tcm within its lumen, was stereotactically placed into the phantom, and the tracer contained in the needle injected into the lesion. Needle placement was primarily guided by the exact coordinates, but also by real-time visualization of the radioactive needle. Pre- and post-localization images were acquired and regions of interest (ROIs) defined. Also after the tracer was injected into the lesion, images of the phantom with and without the lesion were obtained to calculate the percentage of tracer injected outside the lesion. The results of 30 consecutive localization attempts included 25 exact localizations with less than 20% tracer injected outside the lesion, 2 "near misses' with 37-44% injected outside the lesion, and 3 "misses' with 60, 85 and 100% of the tracer being injected outside the lesion. The missed localizations were all in lesions at least 4 cm deep, and all had partially superimposed ROIs, which indicates the needle came very close to the lesion. To conclude, our scintigraphy-guided biplane localization technique for breast phantom lesions successfully localized 90% of all lesions.

Biopsy↗
PubMed1995

Investigation of abnormal appearing thyroid glands on Tc-99m sestamibi breast scintimammography.

Of 507 breast scintimammograms performed using Tc-99m sestamibi, 34 patients were incidentally found to have abnormal appearing thyroid glands. The authors sought to investigate the clinical significance and/or ascertain an extraneous causative factor for these findings. One cold thyroid nodule was detected and was proven benign through biopsy. Two cases of subacute and chronic thyroiditis were proven, and it is possible that additional patients had this disease process. Focal areas of increased thyroid Tc-99m sestamibi uptake were observed in eight patients and probably represent parathyroid adenomas, nonautonomous hyperfunctioning thyroid nodules, or nontoxic multinodular goiter. The results did not yield an extraneous causative factor, underlying pathology, or clinically significant disease in all of the patients investigated, but the findings suggest a need for careful evaluation of any unusual uptake in the thyroid gland and the rest of the image. The authors do not recommend investigation of all abnormal appearing thyroid glands on Tc-99m sestamibi scintimammography. However, clinical correlation should be recommended.

Adult↗
PubMed1995

Scintimammography: the complementary role of Tc-99m sestamibi prone breast imaging for the diagnosis of breast carcinoma.

PURPOSE: To evaluate the complementary role of technetium-99m sestamibi scintimammography in improvement of the sensitivity and specificity of mammography in detection of carcinoma of the breast. MATERIALS AND METHODS: At 5 and 60 minutes after intravenous injection of Tc-99m sestamibi, scintimammograms were obtained in 147 women (age range, 18-73 years; mean age, 47.9 years +/- 10.2 [standard deviation]) with 153 lesions that warranted breast biopsy (102 lesions) or fine-needle aspiration cytologic analysis (51 lesions). There were 113 palpable and 40 nonpalpable lesions. Lesion size on mammograms was 0.8 x 0.6 cm to 15.0 x 11.0 cm (mean, 2.82 cm +/- 1.71 x 2.39 cm +/- 1.56). RESULTS: Scintimammographic findings were true-positive in 47 biopsy-confirmed carcinomas, true-negative in 91 benign lesions, false-positive in 11 lesions with benign histopathologic findings (fibrocystic disease [n = 8] or fibroadenoma [n = 3]), and false-negative in four lesions of infiltrating ductal carcinoma. The sensitivity of scintimammography was 92.2%; specificity, 89.2%; positive predictive value, 81.0%; and negative predictive value, 95.8%. CONCLUSION: The authors conclude that scintimammography is a sensitive test that can improve the detection of breast carcinoma.

Biopsy, Needle↗
PubMed1995

111-indium-DTPA-IgG lung imaging in patients with pulmonary and HIV infection.

111-Indium-DTPA-IgG (111In-IgG) is a new radiopharmaceutical that has been evaluated for the detection of infection without the need for in vitro cell labeling. We prospectively studied this agent in 33 patients suspected of having lung infections, most of whom also had HIV infection, and three patients with HIV infection and diarrhea without lung disease. Anterior and posterior lung images in the upright position were obtained within 24 h after intravenous administration of 2 mCi of 111In-IgG and were read in a blinded fashion by two nuclear medicine physicians. Of 29 patients suspected to have Pneumocystis carinii pneumonia (PCP), the diagnosis was confirmed by bronchoalveolar lavage in 18. Diffusely increased lung uptake of 111In-IgG was found in 17 of 18 patients who had PCP and was normal in 10 of 11 patients without PCP. The intensity of 111In-IgG uptake was related to sever gas exchange abnormality. Two patients with apparent bacterial lung infections had focal accumulation of 111In-IgG while two patients with minor radiographic abnormalities had no increased uptake. Normal lung uptake also occurred in two of three HIV-positive patients who had diarrhea and no lung disease. 111In-IgG appears to be useful in the detection of PCP and other pulmonary infections.

AIDS-Related Opportunistic Infections↗
PubMed1995

Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up.

UNLABELLED: Mammography and physical examination combined have a sensitivity of 85% for the detection of breast carcinoma. Mammography also has a positive predictive value of 15%-30%. The aim of this study was to evaluate the usefulness of scintimammography using 99mTc-sestamibi as a complementary technique to mammography for the detection of breast carcinoma to improve mammography's sensitivity and specificity. METHODS: We studied 100 consecutive patients (mean age 48.3 +/- 10.8 yr) who had 106 lesions warranting biopsy (67 lesions) or fine needle aspiration cytology (FNA) (39 lesions) of the breast. There were 85 palpable and 21 nonpalpable lesions. The size of the lesions on the mammograms were moderate (2.3 +/- 1.8 x 1.9 +/- 1.5 cm). Each patient received 20 mCi 99mTc-sestamibi intravenously. Five and 60 min postinjection, planar breast images in the lateral prone position were obtained. An anterior erect projection was then obtained to visualize the axilla and, if needed, a posterior oblique prone projection. RESULTS: Scintimammography was true-positive in 30 lesions with biopsy-confirmed breast carcinoma; it was true-negative in 65 lesions subsequently proved to be benign. There were nine breast lesions with benign findings in which the scintimammography result was positive (false-positive scintimammography) for cancer. Finally, two lesions with pathologically proven carcinomas demonstrated a negative scintimammographic result. Therefore, in this group, the sensitivity of scintimammography was 93.7% with a specificity of 87.8%; the positive predictive value was 76.9%. The negative predictive value was 97%. CONCLUSION: Scintimammography is a highly sensitive test that improves the specificity of conventional mammography for the detection of breast carcinoma.

Biopsy, Needle↗
PubMed1994

Indium-111 labelled pooled human immunoglobulin imaging to monitor the efficacy of specific therapy for Pneumocystis carinii pneumonia.

Functional imaging is ideally suited to monitoring the effect of specific therapy on disease processes. In this pilot study five patients with AIDS and Pneumocystis carinii pneumonia (PCP) were imaged with Indium-111 labelled pooled human immunoglobulin (111In-HIG) during infection and after therapy for PCP. The lung activity of 111In-HIG, measured as a lung/heart ratio, was calculated in a study performed during infection with PCP and after therapy. In all five patients the lung/heart ratio of 111In-HIG was reduced after treatment. The mean reduction in heart/lung ratio was 27% (range 12%-53%). If these results are confirmed by a larger study, 111In-HIG will be useful in monitoring the response of PCP to therapy in patients with AIDS.

AIDS-Related Opportunistic Infections↗
PubMed1994

Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi.

Imaging techniques currently used for the diagnosis of breast cancer are reviewed and compared. Besides mammography, magnetic resonance imaging, positron emission tomography, and thallium-201 scintimammography, a new role of technetium-99m sestamibi scintimammography is discussed. It is concluded that while mammography remains the procedure of choice in screening asymptomatic women for breast cancer, other imaging methods play an important role in detecting malignancies in symptomatic patients. 99mTc-sestamibi scintimammography has high sensitivity and improves the specificity of conventional mammography for the detection of breast cancer; with this technique, prone imaging is preferable to supine imaging. 99mTc-sestamibi scintimammography thus deserves further study as a screening technique.

Adult↗
PubMed1994

Prone scintimammography in patients with suspicion of carcinoma of the breast.

Mammography and physical examination have a sensitivity of 85 percent for detection of carcinoma of the breast. Mammography also has a positive predictive value of 15 to 30 percent. The aim of this study was to evaluate the usefulness of scintimammography (SMM) as a screening technique for the detection of carcinoma of the breast and compare the test's sensitivity and specificity with that of mammography. We conducted SMM on 59 female patients in whom abnormal mammogram and physical examination warranted biopsy of the breast or fine needle aspiration cytology of the breast, or both. Each patient received 20 millicuries of 99mTc Sestamibi intravenously. Five and sixty minutes postinjection, planar breast images in lateral and posterior oblique views were obtained. In 23 patients with biopsy-confirmed carcinoma of the breast, the SMM result was positive. In 33 patients with benign breast lesions, no increased uptake of Sestamibi was noted in the breast. Five other patients with benign lesions of the breast had false-positive scans. There was one patient with an intraductal carcinoma and a cluster of microcalcifications on mammography without an associated mass, for whom the 99mTc Sestamibi scan was negative. In the group of patients studied, the sensitivity of SMM was 95.8 percent, specificity was 86.8 percent, positive predictive value was 82.1 percent and, most importantly, the negative predictive value for the detection of carcinoma of the breast was 97.1 percent. We conclude in this pilot study that SMM is a highly sensitive test that improves the specificity of conventional mammography for the detection of carcinoma of the breast and deserves further study as a screening technique to potentially reduce the number of mammographically "indicated" biopsies of the breast that yield negative results for carcinoma.

Adult↗
PubMed1993

MR mammographic localization. Work in progress.

The authors present phantom test results for a stereotaxic device that may permit simple, rapid, and accurate needle biopsy and localization of breast lesions detected at contrast material-enhanced magnetic resonance (MR) mammography. The mechanical accuracy of this prototype MR breast localizer is approximately plus or minus 3.5 mm at 5 cm.

Biopsy, Needle↗
PubMed1990

Percutaneous transcatheter arterial embolization of bone and soft tissue tumors.

Arterial embolization was performed in 36 patients with tumors of bone and soft tissue. Embolization was the only treatment in seven patients with benign lesions. Fourteen patients underwent embolization before surgery to obtain hemostasis and/or reduce tumor size. Fifteen patients with inoperable primary bone tumors or skeletal metastases underwent palliative embolization. The best results were obtained in aneurysmal bone cysts.

Bone Cysts↗